Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: Implications for modelling human cancers

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Veliça, Pedro ^a   Davies, Nicholas J ^a   Rocha, Pedro P ^b,c   Schrewe, Heinrich ^b,c   Ride, Jonathan P ^a   Bunce, Chris M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOKETOREDUCTASE 1C; ALDOKETOREDUCTASE 1C1; ALDOKETOREDUCTASE 1C12; ALDOKETOREDUCTASE 1C13; ALDOKETOREDUCTASE 1C14; ALDOKETOREDUCTASE 1C18; ALDOKETOREDUCTASE 1C19; ALDOKETOREDUCTASE 1C2; ALDOKETOREDUCTASE 1C20; ALDOKETOREDUCTASE 1C21; ALDOKETOREDUCTASE 1C3; ALDOKETOREDUCTASE 1C4; ALDOKETOREDUCTASE 1C6; ANDROSTANOLONE; ANDROSTENEDIONE; ESTRONE; OXIDOREDUCTASE; PROGESTERONE; PROSTAGLANDIN D2; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; CARBONYL REDUCTASE (NADPH); PROSTAGLANDIN;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; CANCER RESEARCH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; ENZYME SPECIFICITY; FEMALE; GENETIC CONSERVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LEUKEMIA CELL; MALE; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TESTIS; TISSUE DISTRIBUTION; UTERUS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; METABOLISM; PHYLOGENY; SPECIES DIFFERENCE;

MURINAE; MUS;

ALCOHOL OXIDOREDUCTASES; ANIMALS; HUMANS; MICE; MODELS, BIOLOGICAL; PHYLOGENY; PROSTAGLANDINS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 74549165963     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-121     Document Type: Article

References (44)

1. Jez JM, Penning TM. The aldo-keto reductase (AKR) superfamily: an update. Chem Biol Interact 2001, 130-132:499-525. 10.1016/S0009-2797(00)00295-7, 11306071.
2. Hyndman D, Bauman DR, Heredia VV, Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003, 143-144:621-631. 10.1016/S0009-2797(02)00193-X, 12604248.
3. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 1997, 326(Pt 3):625-636. 1218714, 9307009.
4. Davies NJ, Hayden RE, Simpson PJ, Birtwistle J, Mayer K, Ride JP, Bunce CM. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Cancer Res 2009, 69:4769-4775. 10.1158/0008-5472.CAN-08-4533, 19487289.
5. Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 2009, 1155:33-42. 10.1111/j.1749-6632.2009.03700.x, 19250190.
6. Penning TM, Drury JE. Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007, 464:241-250. 10.1016/j.abb.2007.04.024, 2025677, 17537398.
7. Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, Luong QT, Hayden RE, Vanin EF, Bunce CM. The Aldo-Keto Reductase AKR1C3 Is a Novel Suppressor of Cell Differentiation That Provides a Plausible Target for the Non-Cyclooxygenase-dependent Antineoplastic Actions of Nonsteroidal Anti-Inflammatory Drugs. 2003, 63:505-512.
8. Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S. Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells 2000, 5:111-125. 10.1046/j.1365-2443.2000.00310.x, 10672042.
9. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000, 351:67-77. 10.1042/0264-6021:3510067, 1221336, 10998348.
10. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, Bunce CM. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis. Mutat Res 2008, 662(1-2):67-74.
11. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 2006, 147:5806-5816. 10.1210/en.2006-0627, 16959841.
12. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM, Lin HK. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006, 248:182-191. 10.1016/j.mce.2005.12.009, 16417966.
13. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 2003, 144:2922-2932. 10.1210/en.2002-0032, 12810547.
14. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3(type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008, 75:484-493. 10.1016/j.bcp.2007.09.008, 2245880, 17950253.
15. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 2004, 279:10784-10795. 10.1074/jbc.M313308200, 14672942.
16. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006, 66:2815-2825. 10.1158/0008-5472.CAN-05-4000, 16510604.
17. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3(type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004, 69:795-801. 10.1016/j.steroids.2004.09.014, 15582534.
18. Byrns MC, Penning TM. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact 2009, 178:221-227. 10.1016/j.cbi.2008.10.024, 19010312.
19. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006, 248:126-135. 10.1016/j.mce.2005.10.009, 16338060.
20. Bunce CM, Mountford JC, French PJ, Mole DJ, Durham J, Michell RH, Brown G. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochim Biophys Acta 1996, 1311:189-198. 10.1016/0167-4889(96)00005-5, 8664346.
21. Mills KI, Gilkes AF, Sweeney M, Choudhry MA, Woodgate LJ, Bunce CM, Brown G, Burnett AK. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Lett 1998, 440:158-162. 10.1016/S0014-5793(98)01435-5, 9862446.
22. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 2004, 64:1802-1810. 10.1158/0008-5472.CAN-03-2847, 14996743.
23. Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, Ito S, Watanabe K. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Letters 1999, 462:335-340. 10.1016/S0014-5793(99)01551-3, 10622721.
24. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001, 21:185-210. 10.1002/med.1006, 11301410.
25. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000, 97:4844-4849. 10.1073/pnas.97.9.4844, 18320, 10781090.
26. Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, Biron S, Luu-The V, Tchernof A. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 2006, 191:637-649. 10.1677/joe.1.06365, 17170221.
27. Vergnes L, Phan J, Stolz A, Reue K. A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13. J Lipid Res 2003, 44:503-511. 10.1194/jlr.M200399-JLR200, 12562828.
28. Watanabe K. Prostaglandin F synthase. Prostaglandins & Other Lipid Mediators 2002, 68-69:401-407. 10.1016/S0090-6980(02)00044-8, 12432932.
29. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN, Saunders PT. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer 2009, 9:330. 10.1186/1471-2407-9-330, 2755482, 19758455.
30. Pinto do OP, Wandzioch E, Kolterud A, Carlsson L. Multipotent hematopoietic progenitor cells immortalized by Lhx2 self-renew by a cell nonautonomous mechanism. Exp Hematol 2001, 29:1019-1028. 10.1016/S0301-472X(01)00666-X, 11495708.
31. Pinto do OP, Kolterud A, Carlsson L. Expression of the LIM-homeobox gene LH2 generates immortalized steel factor-dependent multipotent hematopoietic precursors. EMBO J 1998, 17:5744-5756. 10.1093/emboj/17.19.5744, 1170902, 9755174.
32. Higaki Y, Kamiya T, Usami N, Shintani S, Shiraishi H, Ishikura S, Yamamoto I, Hara A. Molecular characterization of two monkey dihydrodiol dehydrogenases. Drug Metab Pharmacokinet 2002, 17:348-356. 10.2133/dmpk.17.348, 15618685.
33. Miura R, Shiota K, Noda K, Yagi S, Ogawa T, Takahashi M. Molecular cloning of cDNA for rat ovarian 20 alpha-hydroxysteroid dehydrogenase (HSD1). Biochem J 1994, 299(Pt 2):561-567. 1138308, 8172618.
34. Maho Ishida K-TC, Hirabayashi K, Nishihara M, Takahashi M. Cloning of Mouse 20α-Hydroxysteroid Dehydrogenase cDNA and Its mRNA Localization during Pregnancy. Journal of Reproduction and Development 1999,
35. Ujihara M, Urade Y, Eguchi N, Hayashi H, Ikai K, Hayaishi O. Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. Arch Biochem Biophys 1988, 260:521-531. 10.1016/0003-9861(88)90477-8, 3124755.
36. Wintergalen N, Thole HH, Galla HJ, Schlegel W. Prostaglandin-E2 9-reductase from corpus luteum of pseudopregnant rabbit is a member of the aldo-keto reductase superfamily featuring 20 alpha-hydroxysteroid dehydrogenase activity. Eur J Biochem 1995, 234:264-270. 10.1111/j.1432-1033.1995.264_c.x, 8529651.
37. Unezaki S, Sugatani J, Masu Y, Watanabe K, Ito S. Characterization of prostaglandin F2 alpha production in pregnant and cycling mice. Biol Reprod 1996, 55:889-894. 10.1095/biolreprod55.4.889, 8879505.
38. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386. 10.1093/carcin/bgp014, 19136477.
39. Piekorz RP, Gingras S, Hoffmeyer A, Ihle JN, Weinstein Y. Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20alpha-hydroxysteroid dehydrogenase. Mol Endocrinol 2005, 19:431-440. 10.1210/me.2004-0302, 15471942.
40. Ikeda S, Okuda-Ashitaka E, Masu Y, Suzuki T, Watanabe K, Nakao M, Shingu K, Ito S. Cloning and characterization of two novel aldo-keto reductases (AKR1C12 and AKR1C13) from mouse stomach. FEBS Lett 1999, 459:433-437. 10.1016/S0014-5793(99)01243-0, 10526179.
41. Faucher F, Cantin L, Pereira de Jesus-Tran K, Lemieux M, Luu-The V, Labrie F, Breton R. Mouse 17[alpha]-Hydroxysteroid Dehydrogenase (AKR1C21) Binds Steroids Differently from other Aldo-keto Reductases: Identification and Characterization of Amino Acid Residues Critical for Substrate Binding. Journal of Molecular Biology 2007, 369:525-540. 10.1016/j.jmb.2007.03.058, 17442338.
42. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948. 10.1093/bioinformatics/btm404, 17846036.
43. Simpson PJ, Tantitadipatak C, Reed AM, Mather OC, Bunce CM, White SA, Ride JP. Characterization of Two Novel Aldo-Keto Reductases from Arabidopsis: Expression Patterns, Broad Substrate Specificity, and an Open Active-Site Structure Suggest a Role in Toxicant Metabolism Following Stress. J Mol Biol 2009, 392:465-480. 10.1016/j.jmb.2009.07.023, 19616008.
44. Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, Pearce C, Sant T, Drayson MT, Bunce CM. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14, PGJ2. Leukemia 2009, 23:292-304. 10.1038/leu.2008.283, 18923439.